-+ 0.00%
-+ 0.00%
-+ 0.00%

LAMY’s Exousia Bio nears closing mid-seven-figure investment to expand lab operations

PUBT·08/04/2026 14:59:17
Listen to the news
LAMY’s Exousia Bio nears closing mid-seven-figure investment to expand lab operations
  • LAMY, now Exousia Bio, is finalizing a mid-seven-figure capital investment to fund its next growth phase.
  • Funds target a lab upgrade and relocation to a Level 2 facility, supporting expanded exosome-based oncology programs.
  • Capital also backs international joint ventures tied to a partner working with a major global pharmaceutical company.
  • NexTel Medical (MAJI) will receive expansion funding for commercial scale-up; Exousia Bio remains MAJI’s sole exosome manufacturer.
  • Closing is expected before Labor Day.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAMY published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608041059ACCESSWRNAPR_____1201314) on August 04, 2026, and is solely responsible for the information contained therein.